Organicell Regenerative Medicine Inc BPSR

Primary Symbol: OCEL

Healthcare Biotechnology

Organicell Regenerative Medicine, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of biological therapeutics for the treatment of degenerative diseases and to provide other related services. RAAM products are used in the healthcare industry administered through doctors and clinics. Its leading product, Zofin (Organicell Flow), is an acellular, biologic therapeutic derived from perinatal sources and is manufactured to retain naturally occurring microRNAs, without the addition or combination of any other substance or diluent. The product contains over 300 growth factors, cytokines, chemokines, and 102 unique microRNAs as well as other exosomes derived from perinatal tissues. It has obtained certain Investigation New Drug (IND), and emergency IND (eIND) approvals from the United States Food and Drug Administration (FDA), including applicable Institutional Review Board (IRB) approvals which authorized the Company to commence clinical trials.

OTCQB:OCEL - Post by User

Organicell Regenerative Medicine Inc

<< Previous

Bullboard Posts

Next >>

Post by indaknownewfieon May 12, 2021 12:09pm

110 Views

Post# 33183116

Organicell In Pakistan for Compassionate use

Zofin approved as well as an additional 60 subject suffering from moderate to Severe covid . Results due at end of June from the second cohort study of 65 persons using Zofn for COVID in India Wondering about their COPD and Osteoarthritis indications as well as their FDA results and partnership with the CDC

<< Previous

Bullboard Posts

Next >>

Invest wiser with BMO's InvestorLine Platform features